Hrain Biotechnology Co., Ltd.
19
5
6
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 19 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Role: lead
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Role: lead
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Role: lead
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Role: lead
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Role: lead
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Role: lead
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Role: lead
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
Role: lead
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
Role: lead
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Role: lead
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Role: lead
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
Role: collaborator
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
Role: lead
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
Role: lead
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL
Role: collaborator
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
Role: collaborator
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Role: collaborator
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
Role: collaborator
Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
Role: collaborator
All 19 trials loaded